Plaque Psoriasis
Participation Information
This study is an open-label study, consisting of a 12-week primary treatment phase and an optional 40-week long-term extension phase in which all eligible subjects will receive tapinarof cream, 1% once daily. At the end of the 12-week primary treatment phase, subjects will have the option to continue for 40 additional weeks of treatment. Subjects who choose not to participate in the optional 40-week long-term extension phase will complete a follow-up visit approximately one week after the end of the primary treatment phase. A stipend of up to $500.00 for 12 week trial participation and $825.00 for the optional extension study.
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 2 - 17 years of age
2.) Have Mild to Moderate Plaque Psoriasis with >3% Body Surface Area Affected
3.) Parental consent
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Non-Plaque variant Psoriasis
2.) Current infection in psoriatic lesions
3.) Previous use of tapinarof
ClinicalTrials.gov Identifier: NCT05172726
